|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:B02BX06
|
|
gptkbp:brand
|
gptkb:Hemlibra
|
|
gptkbp:CASNumber
|
1571117-85-6
|
|
gptkbp:chemicalFormula
|
C6488H10052N1732O2013S44
|
|
gptkbp:developer
|
gptkb:Roche
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
~4-5 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
emicizumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
patients with or without factor VIII inhibitors
prevention of bleeding episodes in hemophilia A
|
|
gptkbp:KEGGID
|
D10541
|
|
gptkbp:legalStatus
|
gptkb:Rx-only_(EU)
prescription only
Rx-only (US)
|
|
gptkbp:macromoleculeType
|
humanized monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
factor IXa and factor X bridging
|
|
gptkbp:notRecommendedFor
|
gptkb:hemophilia_B
gptkb:acquired_hemophilia
|
|
gptkbp:patent
|
gptkb:Roche
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
not assigned (consult physician)
|
|
gptkbp:prescribes
|
children and adults with hemophilia A
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
gptkb:DB13904
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:thrombotic_microangiopathy
headache
injection site reaction
arthralgia
thromboembolism
|
|
gptkbp:storage
|
2°C to 8°C (refrigerated)
|
|
gptkbp:target
|
gptkb:factor_IXa
gptkb:factor_X
|
|
gptkbp:UNII
|
Q2I0K6F1N8
|
|
gptkbp:usedFor
|
gptkb:hemophilia_A
|
|
gptkbp:bfsParent
|
gptkb:Hemlibra
|
|
gptkbp:bfsLayer
|
7
|